Adrenal cortical carcinoma.

R. P. Boushey, A. P. Dackiw

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Adrenal cortical carcinoma is a rare endocrine tumor, and complete surgical resection is the only potentially curative treatment. Accurate preoperative biochemical and radiographic evaluation of the patient who presents with an adrenal mass optimizes patient management and facilitates a complete margin-negative resection of the primary tumor--the most important prognostic variable for long-term survival. Response to mitotane or chemotherapy is modest in patients with advanced disease. It is hoped that an improved understanding of the molecular pathogenesis of this challenging tumor will lead to the development of novel treatment strategies.

Original languageEnglish (US)
Pages (from-to)355-364
Number of pages10
JournalCurrent Treatment Options in Oncology
Volume2
Issue number4
StatePublished - Aug 2001

Fingerprint

Adrenocortical Carcinoma
Mitotane
Neoplasms
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adrenal cortical carcinoma. / Boushey, R. P.; Dackiw, A. P.

In: Current Treatment Options in Oncology, Vol. 2, No. 4, 08.2001, p. 355-364.

Research output: Contribution to journalArticle

Boushey, R. P. ; Dackiw, A. P. / Adrenal cortical carcinoma. In: Current Treatment Options in Oncology. 2001 ; Vol. 2, No. 4. pp. 355-364.
@article{84881a728ee54e35984d9feb7c462d00,
title = "Adrenal cortical carcinoma.",
abstract = "Adrenal cortical carcinoma is a rare endocrine tumor, and complete surgical resection is the only potentially curative treatment. Accurate preoperative biochemical and radiographic evaluation of the patient who presents with an adrenal mass optimizes patient management and facilitates a complete margin-negative resection of the primary tumor--the most important prognostic variable for long-term survival. Response to mitotane or chemotherapy is modest in patients with advanced disease. It is hoped that an improved understanding of the molecular pathogenesis of this challenging tumor will lead to the development of novel treatment strategies.",
author = "Boushey, {R. P.} and Dackiw, {A. P.}",
year = "2001",
month = "8",
language = "English (US)",
volume = "2",
pages = "355--364",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Adrenal cortical carcinoma.

AU - Boushey, R. P.

AU - Dackiw, A. P.

PY - 2001/8

Y1 - 2001/8

N2 - Adrenal cortical carcinoma is a rare endocrine tumor, and complete surgical resection is the only potentially curative treatment. Accurate preoperative biochemical and radiographic evaluation of the patient who presents with an adrenal mass optimizes patient management and facilitates a complete margin-negative resection of the primary tumor--the most important prognostic variable for long-term survival. Response to mitotane or chemotherapy is modest in patients with advanced disease. It is hoped that an improved understanding of the molecular pathogenesis of this challenging tumor will lead to the development of novel treatment strategies.

AB - Adrenal cortical carcinoma is a rare endocrine tumor, and complete surgical resection is the only potentially curative treatment. Accurate preoperative biochemical and radiographic evaluation of the patient who presents with an adrenal mass optimizes patient management and facilitates a complete margin-negative resection of the primary tumor--the most important prognostic variable for long-term survival. Response to mitotane or chemotherapy is modest in patients with advanced disease. It is hoped that an improved understanding of the molecular pathogenesis of this challenging tumor will lead to the development of novel treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=0035436958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035436958&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 355

EP - 364

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 4

ER -